IRVINE, Calif.–(BUSINESS WIRE)–Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that develops and markets new products for the treatment of bladder and bowel dysfunction, today announced the launch of its direct-to-home television advertising campaign. consumers.
the Find true relief focuses on women with any form of urinary incontinence, a large and grossly undertreated population. The campaign aims to reduce the stigma associated with these conditions, raise awareness of the Axonics brand and therapies, and encourage women to see a bladder specialist.
The ads feature women with urinary incontinence who were treated with Axonics’ Sacral Neuromodulation (SNM) therapy after consulting with their doctor. Women speak authentically about the challenges of living with incontinence and how Axonics has provided them with life-changing symptom relief.
The ads encourage viewers to visit FindRealRelief.com, Axonics’ new homepage for patients. This website provides information about Axonics incontinence solutions and invites interested individuals to complete a short symptom questionnaire. Qualified people will then be contacted by a team of nurses with the aim of putting the person in contact with a medical specialist in their community.
The ads are now airing on TV in more than 40 markets across the United States and are expected to run through the end of the year. During the month of May, the advertisements will be presented on national television during shows that are very popular with the target population. the Find true relief The campaign will also include targeted ads on YouTube, Facebook, digital audio and various websites.
“Tens of millions of Americans suffer from urinary incontinence and struggle to find long-term symptom relief,” said John Woock, Ph.D., executive vice president, chief marketing and strategy officer at Axonics. “The company is making this important investment because we are committed to this patient population and it is important that Americans with incontinence have the opportunity to find relief from their symptoms. Our omnichannel strategy will establish the Axonics brand and allow us to engage adults with incontinence across multiple platforms with a consistent message that new, life-changing incontinence therapies are available to them. We are thrilled to launch this TV advertising campaign and are confident that it will continue to drive the expansion of the SNM market and move Axonics on the path to market leadership.
Based in Irvine, Calif., Axonics is a global medical technology company that develops and markets new products for adults with bladder and bowel dysfunction. Axonics recently ranked #1 in the 2021 Deloitte Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences, fintech and energy technology companies in North America.
The Company’s Sacral Neuromodulation (SNM) systems provide patients with overactive bladder and/or fecal incontinence with long-lasting, easy-to-use, safe and clinically effective therapy. Plus, Axonics best-in-class urethral bulking hydrogel, Bulkamid®, provides safe and long-lasting symptom relief for women with stress urinary incontinence (SUI). Overactive bladder affects approximately 87 million adults in the United States and Europe, with an additional 40 million adults estimated to suffer from faecal incontinence. SUI affects approximately 29 million women in the United States alone. Axonics’ clinically proven products are offered in hundreds of medical centers in the United States and abroad. Reimbursement coverage is well established in the United States and is a covered service in most European countries. For more information, visit www.axonics.com.
Statements made in this press release that relate to future plans, events, prospects or performance are forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Words such as “anticipated”, “will expects, “believes”, “anticipates”, “intended” and similar words are intended to identify forward-looking statements. Although these forward-looking statements are based on management’s current expectations and beliefs, these forward-looking statements are subject to a number of risks, uncertainties, assumptions and other factors that could cause actual results Actual results differ materially from the expectations expressed in this press release, including the risks and uncertainties disclosed in Axonics’ filings with the Securities and Exchange Commission, all of which are available online at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, Axonics undertakes no obligation to update or revise forward-looking statements to reflect new information, changed circumstances or unforeseen events.